**ARUP LABORATORIES | aruplab.com**
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

**PATIENT REPORT**

Patient Age/Sex: 32 years Female

**Specimen Collected: 04-Jun-24 13:14**

**Preeclampsia, sFlt-1/PlGF Ratio, S/P** | **Received: 04-Jun-24 13:14** | **Report/Verified: 04-Jun-24 13:17**

| Procedure | Result | Units | Reference Interval |
|---|---|---|---|
| Preeclampsia sFlt-1/PlGF Ratio, S/P | 10 [i1] | ratio | [<=39] |

## Test Information

i1: Preeclampsia sFlt-1/PlGF Ratio, S/P

REFERENCE INTERVAL: Preeclampsia sFlt-1/PlGF Ratio, S/P

The sFlt-1/PlGF ratio is indicated to be used as an aid in the management of the patient and is a prognostic assay intended to stratify hospitalized patients into two risk groups (low risk and high risk of progression to preeclampsia with severe features within two weeks from presentation).

The clinical cutoff for the sFlt-1/PlGF ratio is 40.

If the result of the ratio is greater than or equal to 40, the pregnant woman would be at high risk for progression to preeclampsia with severe features within 2 weeks.

If the result of the ratio is less than 40, the pregnant woman would be at low risk for progression to preeclampsia with severe features within 2 weeks.

The assay results should only be used in conjunction with information available from clinical evaluations and other standard of care procedures. The test result is not to be used to replace clinical judgment.